Investor disappointment as vaccines again come up short, despite the Q3 beat
30/10/24 -"Even the better-than-expected Q3 results failed to impress investors, as GSK’s key vaccines fell short of the street’s estimates, causing worries for future growth. Nonetheless, other areas ..."
Pages
65
Language
English
Published on
30/10/24
You may also be interested by these reports :
17/10/25
The markets were jubilant with Virbac’s Q3 25 beat and a guidance upgrade, especially because the investors, in September 2025, doubted the firm’s ...
06/10/25
Over the week ending 3 October, equity markets delivered another strong performance. In Europe, the STOXX 600 rose 2.9%, driven by a massive rebound ...
03/10/25
We have materially upgraded our earnings estimates for UCB, keeping in view the vigorous uptake of the immunology drug Bimzelx, and a strong support ...
29/09/25
Genmab is strategically acquiring Merus to expand its late-stage portfolio with head and neck cancer treatments, addressing anticipated declines in ...